Table 2.
Correlation of CK7, ELF3, EGFR, EphB4 expression in PBMCs with NSCLC’s clinicopathological characteristics.
| Clinicopathological Parameters | N | CK7 | ELF3 | EGFR | EphB4 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Up-Regulated (%) | χ2 | Up-Regulated (%) | χ2 | Up-Regulated (%) | χ2 | Up-Regulated (%) | χ2 | |||
| p-Value | p-Value | p-Value | p-Value | |||||||
| Gender | Male | 79 | 40 (50.63) | 0.432 | 41 (51.89) | 0.605 | 41 (51.90) | 0.014 | 39 (49.37) | 0.699 |
| Female | 32 | 14 (43.75) | 0.511 | 14 (43.75) | 0.437 | 17 (55.13) | 0.907 | 13 (40.63) | 0.403 | |
| Age (year) | <60 | 46 | 17 (36.96) | 4.299 | 20 (43.47) | 1.158 | 22 (47.83) | 0.617 | 19 (41.30) | 0.969 |
| ≥60 | 65 | 37 (56.92) | 0.038 | 35 (53.84) | 0.282 | 36 (55.38) | 0.432 | 33 (50.77) | 0.325 | |
| Smoking history | No | 46 | 26 (56.52) | 1.949 | 26 (56.52) | 1.528 | 28 (60.87) | 2.338 | 24 (52.17) | 0.895 |
| Yes | 65 | 28 (43.08) | 0.163 | 29 (44.61) | 0.216 | 30 (46.15) | 0.126 | 28 (43.08) | 0.344 | |
| Lesion site | Left lobe | 50 | 25 (50.00) | 0.285 | 24 (48.00) | 0.000 | 26 (52.00) | 0.055 | 21 (42.00) | 0.437 |
| Right lobe | 61 | 28 (45.90) | 0.593 | 30 (49.18) | 0.983 | 31 (50.82) | 0.815 | 30 (49.18) | 0.509 | |
| Histopathological type | SCC | 46 | 19 (41.30) | 1.696 | 20 (43.47) | 1.158 | 22 (47.83) | 0.617 | 16 (34.78) | 4.592 |
| ADC | 65 | 35 (53.85) | 0.193 | 35 (53.84) | 0.282 | 36 (55.38) | 0.432 | 36 (55.38) | 0.032 | |
| Tumor size | ≤3 cm | 24 | 13 (54.17) | 0.316 | 14 (58.33) | 0.853 | 14 (58.33) | 0.387 | 15 (62.50) | 2.856 |
| >3 cm | 86 | 41 (47.67) | 0.574 | 41 (47.67) | 0.356 | 44 (51.16) | 0.534 | 37 (43.02) | 0.091 | |
| Differentiation | Well/Moderate | 86 | 43 (50.00) | 0.279 | 42 (48.83) | 0.078 | 44 (51.16) | 0.182 | 39 (45.35) | 0.344 |
| Poor | 25 | 11 (44.00) | 0.597 | 13 (52.00) | 0.781 | 14 (56.00) | 0.670 | 13 (52.00) | 0.557 | |
| T stage | T2 | 94 | 46 (48.94) | 0.020 | 46 (48.93) | 0.092 | 47 (50.00) | 1.248 | 43 (45.74) | 0.299 |
| T3 | 17 | 8 (47.06) | 0.887 | 9 (52.94) | 0.761 | 11 (64.71) | 0.264 | 9 (52.94) | 0.584 | |
| Lymph node metastasis | N0 | 18 | 5 (27.78) | 3.746 | 7 (38.88) | 0.977 | 5 (27.78) | 5.158 | 6 (33.33) | 1.576 |
| N1–3 | 93 | 48 (52.17) | 0.053 | 47 (51.08) | 0.323 | 52 (56.52) | 0.023 | 45 (48.95) | 0.209 | |
| Distant metastasis | M0 | 109 | 53 (48.62) | 0.000 | 54 (49.54) | 0.000 | 57 (52.29) | 0.004 | 51 (46.79) | 0.000 |
| M1 | 2 | 1 (50.00) | 1.000 | 1 (50.00) | 1.000 | 1 (50.00) | 0.949 | 1 (50.00) | 1.000 | |
| Clinical stage | I/II | 56 | 20 (35.71) | 7.569 | 20 (35.71) | 8.654 | 19 (33.93) | 15.210 | 19 (33.93) | 7.574 |
| III/IV | 55 | 34 (61.82) | 0.006 | 35 (63.63) | 0.003 | 39 (70.91) | 9.62 × 10−5 | 33 (60.00) | 0.006 | |
SCC: squamous cell carcinoma; ADC: adenocarcinoma; up-regulated: the number of patients with gene upregulation; Numbers in bold: p < 0.05.